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Cancer stemness and progression: mitochondria on the stage
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The idea that mitochondrial functions correlate 
with tumor malignancy recently arose together with the 
indication that respiration and processing of different 
nutrients, as well as the generation of reactive oxygen 
species, play a mandatory role during key steps of tumor 
progression. While the Warburg scenario, depending on 
the availability of glycolytic intermediates capable to fuel 
anabolic pathways, has been associated with the metabolic 
demand of growing cells, a metabolic reprogramming 
to enhanced mitochondrial function has been related to 
increased aggressiveness. Indeed, mitochondrial oxidants 
are mandatory to engage epithelial/mesenchymal transition 
[1], while oxidative phosphorylation and ability to exploit 
nutrients by respiration sustain dormancy, resistance to 
therapy and tumor relapse [2].
In line with the above idea, in three very recent 
OncoTarget papers of Michael Lisanti’s laboratory, 
the mitochondria-addicted cancer phenotype has been 
correlated with the achievement of stem-like traits [3-5]. 
They found that the number of mitochondria, as revealed 
by MitoTracker staining, correlates with stemness, 
suggesting that cancer stem cells (CSC) may be selected 
via mitochondrial staining. Noteworthy, a relatively 
large size of cancer cells was also found associated with 
stemness and mitochondrial number/function [3]. The 
latter observation is in contradiction with the idea that 
biomass increase correlates with the Warburg metabolic 
profile, which supports anabolic pathways in terms of 
aminoacid and nucleotide synthesis. Such a paradox is 
only apparent, as pyruvate kinase M2 (PKM2), a key 
regulator of the accumulation of glycolytic intermediates 
needed for cell growth and historically associated with 
a Warburg profile, is also an upstream regulator of the 
transcriptional pathway leading to the generation and 
functional upgrading of mitochondria [1]. Thus, PKM2 
lies at the crossroads between biomass accumulation and 
mitochondria functionalization. On the other hand, Myc 
has been involved in cell reprogramming towards the 
mitochondria-based glutamine metabolism, as well as 
in the control of protein biosynthesis leading to biomass 
increase. Both observations reveal that the link between 
biomass increase and mitochondrial functions is strong, 
although clearly underestimated at present. Lisanti’s 
group strengthened the association of the mitochondria-
rich/anabolic/motile phenotype with stem cell traits using 
a telomerase expression-based model. High telomerase 
expression was found correlated with number/function 
of mitochondria and cell size/biomass [4]. Nutrient 
sensing through sirtuins and PGC1α-mediated increased 
mitochondrial biogenesis are likely to play a central 
role in the acquisition of the mitochondria-rich/stem-
like/anabolic phenotype, and therefore to support CSC 
resistance to therapy [6]. Finally, FGF3 and Wnt1 secreted 
by neighboring cells are able to reprogram cancer cells 
towards this phenotype, which is therefore apparently 
under control of microenvironment [5].
The finding that high mitochondrial mass is 
associated with increased tumor initiation frequency 
but not with increased tumor (mammosphere) size [3] 
point to the involvement of mitochondrial function in 
the maintenance of CSC rather than in their downstream 
clonal expansion. This impacts on the question of 
whether the balance of functional phenotypes within the 
CSC compartment is dynamically regulated by changes 
of metabolic profile. We found that Chronic Myeloid 
Leukemia (CML) cells are capable to expand under 
severe hypoxia as long as (anaerobic) glycolysis and its 
anabolic effects are sustained by glucose availability. 
Glucose exhaustion in hypoxia, while suppressing CML 
cell population expansion, leads to the selection of a 
cell subset endowed with a completely therapy-resistant 
CSC potential. The onset of resistance parallels the fact 
that, while the oncogenetic BCR/Abl protein responsible 
for CML is expressed until glucose is available, it is 
suppressed when glucose is exhausted. This was the first 
study to link metabolism to the loss of oncogene addiction 
(7 and references therein). Thus, a glycolysis-independent 
CSC phenotype seems to foster CML resistance to therapy. 
According to the Lisanti and coworkers’ findings, it is 
straightforward to hypothesize that this CSC subset of 
CML rely on enhanced mitochondrial activity and on 
the oxidation of substrates other than glucose. On the 
other hand, the relationship of telomerase expression 
to mitochondrial activity [4] may provide an intriguing 
explanation to the fact that in hypoxia stem cell potential 
is maximal in normal hematopoietic cells which have 
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undergone one mitotic cycle, while it is lower in cells 
which have either remained quiescent or undergone more 
than one cycle [7 and references therein]. It is tempting 
to speculate that an increased mitochondrial function 
paralleles the activation (from quiescence) of stem cells 
to exploit maximally their potential (highest telomerase 
activity), which is instead rapidly exhausted during the 
following glycolysis-driven clonal expansion.
Collectively, the papers recently published by 
Lisanti’s group together with current literature point to 
the existence, among cancer cell subsets, of a phenotype 
in which several features (as shown in the Figure) are 
intimately associated: i) addiction to mitochondrial 
functions, ii) activation of anabolic pathways, iii) 
achievement of stem-like traits, iv) resistance to stress 
and therapy, v) ability to undergo epithelial/mesenchymal 
transition. Interestingly, this complex phenotype is deeply 
influenced by microenvironmental factors, including 
cancer-associated “supporting” cells such as fibroblasts 
or macrophages (1), cytokines [5] and oxygen/glucose 
shortage [7]. Needless to say, extensive investigation is 
still needed to identify common molecular pathways 
driving the success of the mitochondria-rich/anabolic/
motile CSC, a necessary step in order to define a targeted 
and effective therapeutic strategy against such a strongly 
malignant tumor cell subset.
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